{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:11:28Z","timestamp":1778051488737,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.urolonc.2012.07.012","type":"journal-article","created":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T05:31:07Z","timestamp":1352784667000},"page":"80-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: Results from an Italian biopsy cohort"],"prefix":"10.1016","volume":"32","author":[{"given":"Cosimo","family":"De Nunzio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Presicce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Cancrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2012.07.012_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib2","first-page":"641","article-title":"Molecular markers for prostatic cancer","volume":"2","author":"Castelli","year":"2010","journal-title":"Front Biosci"},{"key":"10.1016\/j.urolonc.2012.07.012_bib3","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1016\/S0021-9258(18)37995-X","article-title":"Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA","volume":"263","author":"Helman","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2012.07.012_bib4","first-page":"458","article-title":"Detection of chromogranin in neuroendocrine cells with a monoclonal antibody","volume":"115","author":"Wilson","year":"1984","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2310\/JIM.0b013e3181f5d610","article-title":"Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer","volume":"58","author":"Reis","year":"2010","journal-title":"J Investig Med"},{"key":"10.1016\/j.urolonc.2012.07.012_bib6","first-page":"108","article-title":"Chromogranin A: Serum marker for prostate cancer","volume":"61","author":"Khan","year":"2011","journal-title":"J Pak Med Assoc"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2012.07.012_bib7","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1093\/annonc\/12.suppl_2.S153","article-title":"Potential clinical value of circulating chromogranin A in patients with prostate carcinoma","volume":"12","author":"Berruti","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib8","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijrobp.2010.12.064","article-title":"Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8\u201310 prostate cancer treated with primary radiotherapy","volume":"81","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2012.07.012_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5301\/RU.2011.8337","article-title":"[Role of neuroendocrine cells in prostate cancer progression]","volume":"78","author":"Sciarra","year":"2011","journal-title":"Urologia"},{"key":"10.1016\/j.urolonc.2012.07.012_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1756-9966-29-166","article-title":"Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2012.07.012_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000200789","article-title":"Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma","volume":"82","author":"Sciarra","year":"2009","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2012.07.012_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.pcan.4501026","article-title":"New circulating biomarkers for prostate cancer","volume":"11","author":"Bensalah","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2012.07.012_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365590701303934","article-title":"Implications of circulating chromogranin A in prostate cancer","volume":"41","author":"Hirano","year":"2007","journal-title":"Scand J Urol Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2012.07.012_bib14","first-page":"25","article-title":"[Chromogranin A (CgA): The influence of various factors in vivo and in vitro, and existing disorders on its concentration in blood]","volume":"62","author":"Glinicki","year":"2011","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.juro.2008.10.163","article-title":"The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy","volume":"181","author":"De Nunzio","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib16","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2005.05.525","article-title":"Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study","volume":"23","author":"Freedland","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/pcan.2010.15","article-title":"Predicting non-organ-confined prostate cancer in men diagnosed after 2000","volume":"13","author":"Caire","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2012.07.012_bib18","first-page":"831","article-title":"Caveolin-1 as a potential high-risk prostate cancer biomarker","volume":"27","author":"Gumulec","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.urolonc.2012.07.012_bib19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.juro.2011.06.052","article-title":"Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng\/ml using an investigational prostate cancer methylation assay","volume":"186","author":"Baden","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5301\/JBM.2010.6116","article-title":"Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy","volume":"25","author":"Puzone","year":"2010","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.urolonc.2012.07.012_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/172460080602100406","article-title":"The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer","volume":"21","author":"Grimaldi","year":"2006","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.urolonc.2012.07.012_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000085929","article-title":"Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free\/total prostate-specific antigen determination","volume":"75","author":"Fracalanza","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2012.07.012_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1442-2042.2008.02175.x","article-title":"Neuroendocrine differentiation in the progression of prostate cancer","volume":"16","author":"Komiya","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2012.07.012_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ijc.2910510205","article-title":"Chromogranin A expression in gastric and colon cancer tissues","volume":"51","author":"Park","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2012.07.012_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-2011-0198","article-title":"Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy","volume":"8","author":"Sarkar","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.urolonc.2012.07.012_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1677\/ERC-07-0089","article-title":"Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy","volume":"14","author":"Alessandro","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2012.07.012_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912002542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912002542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:02:08Z","timestamp":1761040928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912002542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1078143912002542"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.07.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: Results from an Italian biopsy cohort","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}